[go: up one dir, main page]

GB201315136D0 - Cholesterol modulation - Google Patents

Cholesterol modulation

Info

Publication number
GB201315136D0
GB201315136D0 GB201315136A GB201315136A GB201315136D0 GB 201315136 D0 GB201315136 D0 GB 201315136D0 GB 201315136 A GB201315136 A GB 201315136A GB 201315136 A GB201315136 A GB 201315136A GB 201315136 D0 GB201315136 D0 GB 201315136D0
Authority
GB
United Kingdom
Prior art keywords
cholesterol
modulation
cholesterol modulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201315136A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Glasgow Caledonian University
Original Assignee
University of Glasgow
Glasgow Caledonian University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow, Glasgow Caledonian University filed Critical University of Glasgow
Priority to GB201315136A priority Critical patent/GB201315136D0/en
Publication of GB201315136D0 publication Critical patent/GB201315136D0/en
Priority to EP14761394.7A priority patent/EP3035922A1/en
Priority to PCT/GB2014/052585 priority patent/WO2015025180A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30Hormones
    • C12N2501/38Hormones with nuclear receptors
    • C12N2501/385Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB201315136A 2013-08-23 2013-08-23 Cholesterol modulation Ceased GB201315136D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB201315136A GB201315136D0 (en) 2013-08-23 2013-08-23 Cholesterol modulation
EP14761394.7A EP3035922A1 (en) 2013-08-23 2014-08-22 Cholesterol modulation
PCT/GB2014/052585 WO2015025180A1 (en) 2013-08-23 2014-08-22 Cholesterol modulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201315136A GB201315136D0 (en) 2013-08-23 2013-08-23 Cholesterol modulation

Publications (1)

Publication Number Publication Date
GB201315136D0 true GB201315136D0 (en) 2013-10-09

Family

ID=49355860

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201315136A Ceased GB201315136D0 (en) 2013-08-23 2013-08-23 Cholesterol modulation

Country Status (3)

Country Link
EP (1) EP3035922A1 (en)
GB (1) GB201315136D0 (en)
WO (1) WO2015025180A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105250253B (en) * 2015-10-30 2018-06-26 黄恺 Applications of the T0901317 as PARP1 inhibitor
CN105232507B (en) * 2015-10-30 2018-06-26 黄恺 Applications of the GW3965 as PARP1 inhibitor
CN105232561B (en) * 2015-10-30 2018-06-26 黄恺 Application of 22 (the R)-hydroxy cholesterols as PARP1 inhibitor
AU2018346770B2 (en) * 2017-10-05 2021-07-01 National Health Research Institutes Method and composition for treating Hepatocellular carcinoma without viral infection by controlling the lipid homeostasis
WO2020169472A2 (en) * 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
CN117007806A (en) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 Targeting LXR in liver macrophages for controlling slow hepatitis B progression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078972A2 (en) * 1999-06-18 2000-12-28 Cv Therapeutics, Inc. Regulation with binding cassette transporter protein abc1
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels

Also Published As

Publication number Publication date
EP3035922A1 (en) 2016-06-29
WO2015025180A1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
DK3036256T3 (en) Modulation af tumorimmunitet
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
GB2510130B (en) Modulation Unit
DK3077519T3 (en) Cmv-vacciner
HUE063180T2 (en) Panel
GB201317802D0 (en) SmartHaler patent application
EP3042479A4 (en) Enabling modulation mode selection
GB201321070D0 (en) Chirp modulation
GB201315136D0 (en) Cholesterol modulation
AU353644S (en) Stamphousing
IL241596B (en) Immune modulation
DK3056208T3 (en) Immunpotentiator
GB201323006D0 (en) Panel
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
GB201321601D0 (en) Modulator
GB201312727D0 (en) Modulators
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201319432D0 (en) Shifts
GB201318298D0 (en) Modulators
GB201317988D0 (en) Modulators
GB201304473D0 (en) Modulators
GB201304253D0 (en) Cooking Aid
GB201322342D0 (en) Procedure

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)